Allogeneic bone marrow transplantation versus intensification chemotherapy for acute myelogenous leukaemia in first remission: a prospective controlled trial
- 1 February 1988
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 68 (2), 219-226
- https://doi.org/10.1111/j.1365-2141.1988.tb06193.x
Abstract
In 1982 we began a prospective controlled trial to assess the effectiveness of allogeneic bone marrow transplantation and intensive post-remission chemotherapy for patients with acute myelogenus leukaemia in first complete remission. Fourteen patients, 3-45 years of age, who had an HLA-identical sibling donor, received bone marrow transplantation. Twenty-five patients who either lacked an HLA-identical sibling or were over 45 years of age received intensive consolidation chemotherapy including high-dose cytosine arabinoside with or without adriamycin. The actuarial rate of continued complete remission (CCR) at 3 years was significantly higher in the transplantation group than in the chemotherapy group: 70% (95% confidence interval 35-91%) compared with 10% (95% confidence interval 2-30%); P = 0.01. However, the actuarial rate of CCR was not significantly different between the transplantation group and patients under 45 years in the chemotherapy group: 70% (95% confidence interval 35-91%) compared with 17% (95% confidence interval 4-45%), 0.1 > P > 0.05. The actuarial probability of leukaemia relapse was significantly lower in the transplantation group than in the chemotherapy group: 10% (95% confidence interval 4-21%) compared with 88% (95% confidence interval 70-96%), 0.05 > P > 0.001. There was no significant difference between both groups if we compare only the patients who died of non-leukaemic causes: 22% (95% confidence interval 9-42%) versus 25% (95% confidence interval 7-59%), P = NS. In summary, this study shows, that allogeneic bone marrow transplantation is a better anti-leukaemic treatment than is intensive consolidation chemotherapy in patients with AML in first complete remission.This publication has 26 references indexed in Scilit:
- High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot studyBlood, 1985
- Treatment of Acute Myelogenous LeukemiaAnnals of Internal Medicine, 1985
- Bone Marrow Transplantation or Chemotherapy After Remission Induction for Adults with Acute Nonlymphoblastic LeukemiaAnnals of Internal Medicine, 1984
- ELIMINATION OF GRAFT-VERSUS-HOST DISEASE BY IN-VITRO DEPLETION OF ALLOREACTIVE LYMPHOCYTES WITH A MONOCLONAL RAT ANTI-HUMAN LYMPHOCYTE ANTIBODY (CAMPATH-1)The Lancet, 1984
- PROLONGED SURVIVAL IN ACUTE MYELOGENOUS LEUKAEMIA WITHOUT MAINTENANCE CHEMOTHERAPYThe Lancet, 1984
- Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and CyclophosphamideNew England Journal of Medicine, 1983
- BONE-MARROW TRANSPLANTATION FOR ACUTE LEUKAEMIA IN FIRST REMISSIONThe Lancet, 1982
- THE PLACE OF BONE-MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKÆMIAThe Lancet, 1980
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958